Core Insights - Sanofi Pharmaceutical-B (02257) experienced a significant stock price increase, rising over 17% during trading, with a current increase of 15.84% to HKD 11.85, and a trading volume of HKD 15.0443 million [1] Financial Performance - For the first half of 2025, Sanofi Pharmaceutical-B reported other income of USD 12.4 thousand, a year-on-year decline of 87.4% [1] - The company recorded a loss attributable to shareholders of USD 3.698 million, which represents a year-on-year reduction of 91% [1] - The basic loss per share was USD 0.04 [1] - The reduction in losses was attributed to decreased fair value losses on financial assets, reduced R&D expenses, lower administrative expenses, and decreased fair value losses on financial liabilities [1] Product Pipeline - Sanofi Pharmaceutical-B's core products include STP705, STP707, and STP122G, with STP705 being the most advanced in development and expected to be the company's first commercial product by 2025 [2] - STP705 targets both TGF-β1 and COX-2, making it the first and only siRNA drug to achieve positive Phase II clinical results in cancer treatment [2] - In the Phase II clinical trial for skin basal cell carcinoma, the 180ug dosage group achieved a 100% complete clearance rate [2] - The company is expanding STP705's indications, having initiated Phase II clinical trials for scars, Phase I clinical trials for adult abdominal liposuction, and Phase I clinical trials for liver cancer [2] - STP705 has also received orphan drug designation for the treatment of cholangiocarcinoma and primary sclerosing cholangitis [2]
港股异动 | 圣诺医药-B(02257)盘中涨超17% 中期股东应占亏损同比收窄91% STP705有望于年内完成商业化